171 related articles for article (PubMed ID: 28921649)
1. Dose Finding Versus Speed in Seamless Immuno-Oncology Drug Development.
Mayawala K; Tse A; Rubin EH; Jain L; de Alwis DP
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S143-S145. PubMed ID: 28921649
[No Abstract] [Full Text] [Related]
2. Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development Strategies.
Zhou L; Higashimori M; Shen K; Zhang Z; Sheng J; Xu H; Horiuchi M; Ichikawa K; Al-Huniti N; Zhou D
Clin Pharmacol Ther; 2019 Jun; 105(6):1303-1320. PubMed ID: 30802932
[No Abstract] [Full Text] [Related]
3. [Antineoplastic agents and biologic response modifiers in oncologic hematology].
Cabrera Marín JR; Briz del Blanco M
Rev Clin Esp; 1999 Apr; 199 Suppl 1():3-13. PubMed ID: 10422445
[No Abstract] [Full Text] [Related]
4. Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development.
Faucette S; Wagh S; Trivedi A; Venkatakrishnan K; Gupta N
Clin Transl Sci; 2018 Mar; 11(2):123-146. PubMed ID: 29266809
[No Abstract] [Full Text] [Related]
5. The rationale of dose-response curves in selecting cancer drug dosing.
Martin JH; Dimmitt S
Br J Clin Pharmacol; 2019 Oct; 85(10):2198-2204. PubMed ID: 31077412
[TBL] [Abstract][Full Text] [Related]
6. Drug Exposure to Establish Pharmacokinetic-Response Relationships in Oncology.
Solans BP; Garrido MJ; Trocóniz IF
Clin Pharmacokinet; 2020 Feb; 59(2):123-135. PubMed ID: 31654368
[TBL] [Abstract][Full Text] [Related]
7. Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.
Ji Y; Jin JY; Hyman DM; Kim G; Suri A
Clin Transl Sci; 2018 Jul; 11(4):345-351. PubMed ID: 29392871
[No Abstract] [Full Text] [Related]
8. Dose matters: Direct killing or immunoregulatory effects of natural polysaccharides in cancer treatment.
Pang G; Wang F; Zhang LW
Carbohydr Polym; 2018 Sep; 195():243-256. PubMed ID: 29804974
[TBL] [Abstract][Full Text] [Related]
9. Early-drug development in the era of immuno-oncology: are we ready to face the challenges?
Ochoa de Olza M; Oliva M; Hierro C; Matos I; Martin-Liberal J; Garralda E
Ann Oncol; 2018 Aug; 29(8):1727-1740. PubMed ID: 29945232
[TBL] [Abstract][Full Text] [Related]
10. Similar neurotoxicity of an alternating compared to a continuous low-dose schedule of thalidomide for relapsed/refractory multiple myeloma.
Mangiacavalli S; Albani G; Caravita T; Cocito F; Pascutto C; Zappasodi P; Bringhen S; Palumbo A; Cazzola M; Corso A
Leuk Lymphoma; 2012 Mar; 53(3):514-5. PubMed ID: 22141736
[No Abstract] [Full Text] [Related]
11. [The current potentials and outlook for drug therapy in oncology].
Gershanovich ML; Borisov VI; Sidorenko IuS; Tiuliandin SA; Gorbunova VA
Vopr Onkol; 1995; 41(2):116-24. PubMed ID: 7483406
[No Abstract] [Full Text] [Related]
12. Phase I trial of pomalidomide given for patients with advanced solid tumors.
Cooney MM; Nock C; Bokar J; Krishnamurthi S; Gibbons J; Rodal MB; Ness A; Remick SC; Dreicer R; Dowlati A
Cancer Chemother Pharmacol; 2012 Nov; 70(5):755-61. PubMed ID: 22875080
[TBL] [Abstract][Full Text] [Related]
13. How to address challenges and opportunities in pediatric cancer drug development?
Moreno L; DuBois SG; Marshall LV; Fox E; Carceller F; Pearson AD
Expert Opin Drug Discov; 2020 Aug; 15(8):869-872. PubMed ID: 32421361
[No Abstract] [Full Text] [Related]
14. Pediatric Development of Molecularly Targeted Oncology Drugs.
Patel SK; Leong R; Zhao H; Barone A; Casey D; Liu Q; Burckart GJ; Reaman G
Clin Pharmacol Ther; 2018 Aug; 104(2):384-389. PubMed ID: 29226303
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapeutic strategies for neoplasia.
Talmadge JE
Dev Biol Stand; 1992; 77():17-28. PubMed ID: 1426659
[No Abstract] [Full Text] [Related]
16. Ofatumumab and its role as immunotherapy in chronic lymphocytic leukemia.
Sandhu S; Mulligan SP
Haematologica; 2015 Apr; 100(4):411-4. PubMed ID: 25828085
[No Abstract] [Full Text] [Related]
17. Clinical and Regulatory Aspects of Companion Diagnostic Development in Oncology.
Jørgensen JT; Hersom M
Clin Pharmacol Ther; 2018 Jun; 103(6):999-1008. PubMed ID: 29197081
[TBL] [Abstract][Full Text] [Related]
18. High-throughput Strategy Accelerates the Progress of Marine Anticancer Peptide Drug Development.
Lyu P; Kwok HF
Recent Pat Anticancer Drug Discov; 2019; 14(1):2-4. PubMed ID: 30474536
[No Abstract] [Full Text] [Related]
19. Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development.
Gao W; Liu J; Shtylla B; Venkatakrishnan K; Yin D; Shah M; Nicholas T; Cao Y
CPT Pharmacometrics Syst Pharmacol; 2024 May; 13(5):691-709. PubMed ID: 37969061
[TBL] [Abstract][Full Text] [Related]
20. Accelerating anticancer drug development - opportunities and trade-offs.
Nass SJ; Rothenberg ML; Pentz R; Hricak H; Abernethy A; Anderson K; Gee AW; Harvey RD; Piantadosi S; Bertagnolli MM; Schrag D; Schilsky RL
Nat Rev Clin Oncol; 2018 Dec; 15(12):777-786. PubMed ID: 30275514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
